On July 6, a patient at UC San Diego received the experimental cancer drug rebecsinib. Before reaching that patient, the drug had been tested against tumor models aboard the International Space Station.
The clinical trial is small. It is a Phase 1 study, designed principally to establish a usable dose and evaluate safety in people with difficult blood cancers. Nobody yet knows whether rebecsinib will become an approved medicine. But the sequence is worth watching: researchers sent living cancer models into orbit, studied how they behaved and responded to treatment, and brought the work back into a development program that has now reached patients.
For investors accustomed to thinking of space as a business of rockets and satellites, medicine introduces a different kind of customer. A pharmaceutical company can justify an expensive experiment if it helps rescue a useful compound or improve an important treatment. The cargo may fit inside a small laboratory box. Most of its eventual value can reside in the knowledge that comes home.
I think drug development is becoming one of the strongest reasons to build a commercial economy in orbit. The encouraging evidence is already spread across a clinical trial, a pharmaceutical collaboration and a business that wants to collect royalties on formulations developed in microgravity. Each gives space companies a reason to fly again.
A laboratory with another setting
Chemists routinely change temperature, pressure and solvents to see what a molecule will do. Orbit gives them access to a condition that is much harder to sustain on Earth: microgravity.
The spacecraft and everything inside it are falling around the planet together. Gravity still exists, but the contents of a laboratory experience very little apparent weight. Particles settle less readily. Buoyancy-driven currents weaken. Molecules can assemble into crystals under different conditions, sometimes producing a more uniform population or a structure that is easier to examine.
The useful result depends on the experiment. A large, well-ordered protein crystal can help researchers determine the shape of a biological target. A suspension of smaller, more uniform drug crystals may be easier to inject. Different arrangements of the same small molecule, called polymorphs, can change how a medicine dissolves or how well it survives storage. Bigger crystals are therefore only one possible goal.
Living cells add another possibility. A tumor organoid is a small, three-dimensional model grown from cells, often taken from a patient. Spaceflight can alter the stresses those cells experience and the biological programs they activate. Researchers can use those changes to investigate disease and test treatments under conditions that a conventional dish does not reproduce.
That makes an orbital experiment a useful companion to work on Earth. Ground controls and follow-up studies establish which effects are useful and which belong to the peculiar conditions of the flight. A faster change in a cell model still has to earn its relevance to a human disease.
Catriona Jamieson’s team at UC San Diego has pursued that route with cancer stem cells, the cells that can help a tumor regenerate after treatment. Rebecsinib’s development focuses on ADAR1, an RNA-editing enzyme implicated in cancer survival. The clinical registry describes the compound as a spliceosome modulator that inhibits ADAR1, connecting it to the machinery cells use to process genetic messages.
Jamieson’s team tested the drug in orbital cancer research on multiple Axiom missions. Aspera Biomedicines, the private company sponsoring the clinical trial, now has a tangible milestone to follow: human dosing. UC San Diego reported that the registered study plans to enroll 28 participants with relapsed or refractory secondary acute myeloid leukemia or higher-risk myelofibrosis.
Aspera earns a place on the watchlist because it owns a drug-development program. Its eventual value will depend on clinical results and the rights to a useful medicine. The space work is part of how it hopes to get there. Investors should follow the dose findings and patient outcomes as closely as the next launch.
The lesson inside a syringe
Merck offers a more mature example of why a pharmaceutical company would bother with orbit.
Its cancer medicine Keytruda is an antibody, a large protein with a complicated shape. Delivering a concentrated dose of such a molecule through a small injection presents a physical problem: the formulation has to flow through a needle, remain stable and behave predictably once administered. A medicine can work biologically and still be awkward to deliver.
In experiments flown to the ISS in 2017, Merck researchers studied crystallization of pembrolizumab, Keytruda’s active ingredient. Their 2019 paper reported a relatively uniform population of crystals around 39 micrometers across. The matched ground experiments produced two populations, around 13 and 102 micrometers. The orbital suspensions were less viscous and settled more uniformly.
The researchers then took the lesson home. They applied what they had learned to experiments on Earth, using rotational mixing and temperature control to produce small, uniform crystalline suspensions with properties suitable for injectable-formulation research. The useful output of spaceflight included a better way to run a terrestrial process.
In September 2025, the FDA approved Keytruda Qlex, a subcutaneous version of the treatment. Merck says administration takes about one minute on the three-week schedule or two minutes on the six-week schedule, compared with a 30-minute intravenous infusion of Keytruda. A healthcare professional administers it. Those figures describe drug administration, rather than the duration of an entire appointment.
NASA credits the orbital research with early insights into particle structure and size that informed formulation development. The approved product combines pembrolizumab with an enzyme, berahyaluronidase alfa, that helps the medicine disperse under the skin. It should not be confused with a commercial supply of space-grown crystals, or with proof that the orbital experiments alone produced the approved injection.
A drug company can extract value from space research while doing its manufacturing on the ground. It can spread the cost of an experiment across years of development and, if successful, many patients.
Merck (NYSE: MRK) belongs on a space-medicine watchlist as an experienced pharmaceutical user. Its investment case remains tied to its much larger drug business. The orbital work shows what an established company might buy: help solving a formulation problem with a direct connection to the treatment experience.
A drug company commits to orbital research
In May 2026, Varda Space Industries announced a collaboration with United Therapeutics to study improved formulations of small-molecule medicines for rare pulmonary disease across multiple orbital missions.
United Therapeutics (Nasdaq: UTHR) brings the drug-development experience and an existing focus on patients with serious lung disease. Varda supplies an autonomous processing platform and a way to return the material. Their stated goals include improvements in stability, bioavailability and delivery. Bioavailability is the share of a dose that reaches the circulation, one of the basic determinants of how effectively a medicine can be used.
For UTHR, the appeal is a new route to improve medicines within a field it already knows. For Varda, the collaboration gives its pharmaceutical operation a named commercial counterpart with a reason to assess the results and commission further work. Financial terms were not disclosed, and the announcement describes development work rather than an approved space-manufactured therapy.
Varda has already addressed a less glamorous prerequisite: whether a processed pharmaceutical sample can survive the trip home. Its work on ritonavir recovered an orbital batch of the drug’s Form III and studied the stability of flight samples and controls after return to Earth. The company reported that the samples retained their physical and chemical stability through the mission.
Form III can also be made on Earth. Varda’s experiment established that it could process the material in orbit and recover an intact sample for laboratory analysis.
Varda’s larger ambition is to own more of the value of the medicine it helps create. Reentry equipment gets a sample home. A successful formulation, and enforceable rights to it, could earn money for much longer than a single flight. The United Therapeutics collaboration gives that ambition a practical setting in which to be tested.
The public stock with a royalty experiment
Among listed companies, Redwire (NYSE: RDW) provides a particularly direct way to follow the commercial machinery of space pharmaceuticals. Its PIL-BOX, short for Pharmaceutical In-Space Laboratory, gives researchers a standardized system for crystallization experiments in orbit.
In August 2025, Redwire created SpaceMD to develop and sell or license seed crystals grown in space. A seed crystal provides a starting pattern for further crystal growth. If the desired form can be reproduced on Earth, an orbital batch could help establish a much larger terrestrial production process.
The model puts a small amount of space-grown material at the beginning of a pharmaceutical supply chain. It also gives SpaceMD a possible source of income beyond equipment and experimental services.
The subsidiary’s launch included a licensing agreement with ExesaLibero Pharma, a private drug developer working on ELP-004 for bone disease. The announced arrangement gives SpaceMD royalties from commercial sales of resulting pharmaceutical products. Those royalties depend on successful development and eventual sales; announcing the agreement creates no such revenue by itself. But the contract shows that both parties see something worth owning in the outcome of the experiment.
Redwire’s August 2026 update reported 54 PIL-BOX systems flown to the ISS and successful crystallization of 45 distinct compounds. More telling for the business is its next capacity decision: SpaceMD signed for a mission on SpaceX’s Starfall spacecraft, planned for 2028, with room for up to 32 PIL-BOXes.
That mission remains ahead. It nevertheless shows a company preparing to run larger groups of experiments on a dedicated commercial vehicle, rather than relying entirely on spare laboratory space aboard a crewed station.
RDW is still a diversified space and defense company. I would follow repeat pharmaceutical customers, the movement of specific compounds into clinical development, and eventual licensing receipts. Those developments would connect an interesting capability to a business that shareholders can measure.
A startup building for larger batches
BioOrbit approaches the opportunity from the manufacturing end. The British startup is developing equipment for crystallizing biologic medicines in microgravity, with the longer-term aim of making concentrated formulations easier to deliver.
Its Baby BOX-E payload flew to the ISS on SpaceX CRS-34 in May 2026 and has since returned to Earth. Mission partner ICE Cubes describes autonomous operation in the station’s Columbus module and a modular design intended to expand from milliliter-scale work toward much larger volumes. BioOrbit reported in July that the first payload demonstrated scalable insulin crystallization and that the returned samples were undergoing analysis.
Regulators and drug companies will need evidence about purity, consistency, stability and control of the process. Larger equipment will also have to preserve whatever advantage appeared in the smaller batch.
BioOrbit now has returned material to show potential partners. Sample analysis and repeat runs can tell them whether the process offers a useful way to formulate their medicines. More convenient injections remain a development goal, with potential benefits for patients who currently spend hours at a treatment center.
Varda, BioOrbit and Aspera offer three different private-company opportunities to watch. Varda combines pharmaceutical processing with sample return. BioOrbit is pursuing a scalable crystallization process. Aspera is advancing a therapeutic candidate. ExesaLibero adds another drug developer to the list, with a royalty agreement that gives Redwire a contractual interest in its success. These companies remain private; their progress can inform a public-market view without providing an ordinary stock-market entry point.
Why the economics can work earlier than expected
A pharmaceutical experiment has an advantage over many proposed space industries: the useful output can be tiny.
A better crystal structure is information. A seed crystal may enable repeated production on the ground. An improved drug formulation can be licensed. These routes allow an orbital mission to contribute to a large terrestrial business without carrying that business’s entire physical output through the atmosphere.
Launch costs have been falling. A 2026 study by Alessio Terzi and Francesco Nicoli assembled data on more than 4,400 launches and estimated that the average cost of sending a kilogram to orbit fell from $87,023 in 1960 to $3,868 in 2025. Their analysis also found substantial cost reductions as cumulative payload increased.
The historical decline in launch costs makes access more plausible; the scientific value of the returned material determines whether a particular mission is worth paying for.
The most promising early customer has a specific, expensive problem: a compound that dissolves poorly, an antibody formulation too viscous to inject, or a protein whose structure remains frustratingly unclear. A useful disease model offers another reason to fly. Each is a narrower purchasing decision than a commitment to an enormous orbital factory.
That is why the United Therapeutics collaboration and the SpaceMD royalty agreement deserve attention. They connect flight activity to recognizable pharmaceutical objectives. The next evidence I want to see is a customer returning after examining the first results, then committing more compounds or a larger development budget.
This also fits the argument in The Problem With Treating Biology Like Software: better predictions still need experimental contact with living systems. An orbital laboratory could generate observations that improve a terrestrial research program, including one driven by AI. Its contribution would be a new source of evidence, tested against what happens on the ground and ultimately in patients.
This article is for information and discussion, not personalized investment advice. Experimental success does not establish clinical efficacy or regulatory approval.
Sources
UC San Diego, “Rebecsinib Clinical Trial Means New Options for Blood Cancer,” August 5, 2026. First patient treatment date, orbital research and clinical context.
ClinicalTrials.gov, NCT07250646: Phase 1 study of rebecsinib. Sponsor, design, planned enrollment and primary safety objectives.
Reichert et al., “Pembrolizumab microgravity crystallization experimentation,” npj Microgravity, 2019. Matched orbital and terrestrial crystallization results and application to ground-based formulation work.
NASA, “Space Station Research Informs New FDA-Approved Cancer Therapy,” April 2, 2026. The agency’s description of the research contribution to formulation development.
Merck, FDA approval announcement for Keytruda Qlex, September 19, 2025. Composition, healthcare-professional administration and administration times.
Varda and United Therapeutics, collaboration announcement, May 13, 2026. Planned multi-mission small-molecule formulation work for pulmonary disease.
Varda, “A study on the stability of ritonavir form III processed in orbit and returned to Earth,” April 8, 2026. Pharmaceutical processing, sample stability and recovery results.
Redwire, SpaceMD formation and ExesaLibero royalty agreement, August 4, 2025. Seed-crystal licensing model and contingent royalties.
Redwire, planned SpaceMD Starfall mission, August 6, 2026. Reported PIL-BOX activity and planned 2028 capacity.
ICE Cubes, “Baby BOX-E: scaling drug crystallisation in orbit.” BioOrbit flight hardware, autonomous operations, return and intended scaling architecture.
BioOrbit, returned Baby BOX-E payload update, July 8, 2026. Company-reported insulin crystallization demonstration and ongoing sample analysis.
Terzi and Nicoli, “From Sputnik to Starship: Estimating the experience curve of space launch technology,” 2026; institutional repository. Historical launch-cost estimates and technological learning analysis.